SSE

BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®

Retrieved on: 
Tuesday, September 19, 2023
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Biologics license application, BGNE, Prescription Drug User Fee Act, Civil service commission, Marketing, ODD, Survival, Advanced Therapy Medicinal Product, Cancer, Quality of life, Medicine, Committee, SSE, European Commission, Patient, Physician, ESCC, Diagnosis, Committee for Medicinal Products for Human Use, Rare, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, PD-L1, Food, Caregiver, Safety, Tislelizumab, Pharmaceutical industry, BeiGene

“We are excited to announce the European Commission approval and the FDA filing acceptance for tislelizumab, having recently regained full global rights to this important medicine.

Key Points: 
  • “We are excited to announce the European Commission approval and the FDA filing acceptance for tislelizumab, having recently regained full global rights to this important medicine.
  • The study enrolled 513 patients from 132 research sites in 11 countries in Europe, Asia and North America.
  • The FDA has assigned a target action date in the second half of 2024, under the Prescription Drug User Fee Act.
  • The FDA also granted tislelizumab Orphan Drug Designation (ODD) for the treatment of previously untreated advanced or metastatic ESCC.

BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)

Retrieved on: 
Tuesday, September 19, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Monoclonal antibody, BGNE, Cancer, Quality of life, SSE, OX40, LAG3, Patient, Medicine, European, Entrepreneurship, PD-L1, Safety, Tislelizumab, Pharmaceutical industry, BeiGene, HPK1, Novartis

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab).

Key Points: 
  • BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab).
  • “BeiGene will continue to work with Novartis on development, regulatory and manufacturing priorities.
  • BeiGene has agreed to provide Novartis with ongoing clinical supply of TEVIMBRA to support its clinical trials.
  • Under the agreement, Novartis was responsible for regulatory submissions and had the right to commercialize in these licensed countries following regulatory approval.

Research Demonstrates Healthcare Sector Lags in Cybersecurity Investment Despite Higher Level of Risk for Attacks

Retrieved on: 
Tuesday, September 19, 2023
Software, Practice Management, Internet, Health, Data Management, Health Technology, Technology, Security, Cloud, Insurance, Software as a service, Clinical trial, DLP, Research, Organization, Security Service, SSE, Trust, Sky High, Risk, Data, PHI, Shadow IT, Pharmaceutical industry, Medical imaging, Medical device

Skyhigh Security today released the Skyhigh Security Cloud Adoption and Risk Report, Healthcare Edition , which investigates the state of cloud security in healthcare organizations, including patient care facilities and healthcare technology companies.

Key Points: 
  • Skyhigh Security today released the Skyhigh Security Cloud Adoption and Risk Report, Healthcare Edition , which investigates the state of cloud security in healthcare organizations, including patient care facilities and healthcare technology companies.
  • While healthcare parallels other sectors in cloud adoption trends, it faces distinct obstacles regarding data security and trust in the cloud.
  • The report shows that 86% of healthcare organizations have experienced data theft compared to only 80% across all industries.
  • But despite the elevated threat level, only 51% of healthcare organizations are committed to investing more in cybersecurity, versus 56% across all industries.

Autoliv and Great Wall Motor to cooperate on advanced automotive safety technologies

Retrieved on: 
Friday, September 22, 2023
Original equipment manufacturer, WEY, Great Wall Motor, ORA, SSE, GWM, TANK, Commons-based peer production, Transport, NYSE, Safety, Great Wall of China, Autoliv

SHANGHAI, Sept. 22, 2023 /PRNewswire/ -- Autoliv China, a division of Autoliv, Inc. (NYSE: ALV) and (SSE: ALIVsdb), the worldwide leader in automotive safety systems, and Great Wall Motor ("GWM"), a leading vehicle manufacturer based in China, intend to collaborate to address opportunities and challenges in the rapidly evolving global automotive landscape.

Key Points: 
  • SHANGHAI, Sept. 22, 2023 /PRNewswire/ -- Autoliv China, a division of Autoliv, Inc. (NYSE: ALV) and (SSE: ALIVsdb), the worldwide leader in automotive safety systems, and Great Wall Motor ("GWM"), a leading vehicle manufacturer based in China, intend to collaborate to address opportunities and challenges in the rapidly evolving global automotive landscape.
  • GWM produces and sells vehicles under its own branding, such as Great Wall, Haval, WEY, TANK, and POER.
  • Autoliv has worked with GWM since 2003, when Autoliv developed and began supplying seat belts for Haval SUVs.
  • The strategic cooperation aims to drive innovation through collaboration around advanced technologies with a focus on quality.

Autoliv and Great Wall Motor to cooperate on advanced automotive safety technologies

Retrieved on: 
Friday, September 22, 2023
Original equipment manufacturer, WEY, Great Wall Motor, ORA, SSE, GWM, TANK, Commons-based peer production, Transport, NYSE, Safety, Great Wall of China, Autoliv

SHANGHAI, Sept. 22, 2023 /PRNewswire/ -- Autoliv China, a division of Autoliv, Inc. (NYSE: ALV) and (SSE: ALIVsdb), the worldwide leader in automotive safety systems, and Great Wall Motor ("GWM"), a leading vehicle manufacturer based in China, intend to collaborate to address opportunities and challenges in the rapidly evolving global automotive landscape.

Key Points: 
  • SHANGHAI, Sept. 22, 2023 /PRNewswire/ -- Autoliv China, a division of Autoliv, Inc. (NYSE: ALV) and (SSE: ALIVsdb), the worldwide leader in automotive safety systems, and Great Wall Motor ("GWM"), a leading vehicle manufacturer based in China, intend to collaborate to address opportunities and challenges in the rapidly evolving global automotive landscape.
  • GWM produces and sells vehicles under its own branding, such as Great Wall, Haval, WEY, TANK, and POER.
  • Autoliv has worked with GWM since 2003, when Autoliv developed and began supplying seat belts for Haval SUVs.
  • The strategic cooperation aims to drive innovation through collaboration around advanced technologies with a focus on quality.

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Retrieved on: 
Wednesday, September 20, 2023
Linda, Malignancy, Obstetrics, Photocure, Peking Union Medical College Hospital, Medicine, NDA, Cervical cancer, Woman, Cevira, Human papillomavirus infection, Death, Incidence, SSE, Peking Union Medical College, Patient, HSIL, Cancer, HPV, Gynaecology, Mortality, WHO, Phase, NMPA, Safety, Bladder cancer, Pharmaceutical industry, Birth control, Colposcopy

Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.

Key Points: 
  • Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
  • This study is a prospective, randomized, double-blind, placebo-controlled international multicenter Phase III clinical trial designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • "It is exciting to see that the Phase III clinical trial for Cevira has met its primary endpoint.
  • This press release may contain product details and information which are not valid, or a product is not accessible, in your country.

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Retrieved on: 
Wednesday, September 20, 2023
Linda, Malignancy, Obstetrics, Photocure, Peking Union Medical College Hospital, Medicine, NDA, Cervical cancer, Woman, Cevira, Human papillomavirus infection, Death, Incidence, SSE, Peking Union Medical College, Patient, HSIL, Cancer, HPV, Gynaecology, Mortality, WHO, Phase, NMPA, Safety, Bladder cancer, Pharmaceutical industry, Birth control, Colposcopy

Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.

Key Points: 
  • Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
  • This study is a prospective, randomized, double-blind, placebo-controlled international multicenter Phase III clinical trial designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • "It is exciting to see that the Phase III clinical trial for Cevira has met its primary endpoint.
  • This press release may contain product details and information which are not valid, or a product is not accessible, in your country.

iboss Announces Azure Cloud Security Gateways: A Revolutionary Extension of Its Zero Trust SSE into Azure

Retrieved on: 
Tuesday, September 19, 2023
Cloud, Multi-factor authentication, MFA, SSO, Single sign-on, Virtual Network Computing, Policy, Virtual private network, DLP, Azure Virtual Desktop, Organization, VPN, SSE, RDP, AVD, Temple of Azure Clouds, Connectivity, Civil Service Protection and Training Commission, Architecture, CASB, Video game, Online shopping, Internet service provider, Zero trust security model, Azure

BOSTON, Sept. 19, 2023 /PRNewswire-PRWeb/ -- In an age where cybersecurity has become a paramount concern for businesses moving datacenter infrastructure into Azure, the need to migrate the functions of datacenter network security appliances into Azure is critical. iboss, the leading name in Zero Trust, unveils its latest groundbreaking capability: the Azure Cloud Security Gateways. This new feature of iboss' Zero Trust Security Service Edge (SSE) provides security directly within Azure, transforming how businesses manage and safeguard their digital ecosystems.

Key Points: 
  • iboss, the leading name in Zero Trust, unveils its latest groundbreaking capability: the Azure Cloud Security Gateways.
  • This new feature of iboss' Zero Trust Security Service Edge (SSE) provides security directly within Azure, transforming how businesses manage and safeguard their digital ecosystems.
  • Solution: The Azure Cloud Security Gateways by iboss provide instant security within Azure and its private Virtual Networks.
  • Paul Martini, CEO of iboss, comments, "The Azure Cloud Security Gateways are not just another feature added to our platform.

ACX Partners With the Athens Stock Exchange in Greece to Develop Carbon Market in the region

Retrieved on: 
Tuesday, September 19, 2023
Carbon, Private sector, Partnership, ACX, United Nations, ABU, Carbon Market, United Nations Environment Programme Finance Initiative, Sustainable Stock Exchanges Initiative, Athens Exchange, SSE, Climate change, United, European, Entrepreneurship, Ecosystem, Renewable energy, EU

SINGAPORE, ATHENS, Greece and ABU DHABI, UAE, Sept. 19, 2023 /PRNewswire/ -- ACX (AirCarbon Exchange) and the Athens Stock Exchange (ATHEX) are delighted to establish a partnership to explore the development of a Voluntary Carbon Market in Greece, with the goal of creating a transparent and efficient market for Voluntary Carbon Credits.

Key Points: 
  • SINGAPORE, ATHENS, Greece and ABU DHABI, UAE, Sept. 19, 2023 /PRNewswire/ -- ACX (AirCarbon Exchange) and the Athens Stock Exchange (ATHEX) are delighted to establish a partnership to explore the development of a Voluntary Carbon Market in Greece, with the goal of creating a transparent and efficient market for Voluntary Carbon Credits.
  • This is the latest step in ACX's bold ambition to operate the world's largest environmental exchange network and the new Carbon Market in Greece will represent ACX's first base in continental Europe.
  • Thomas McMahon, ACX Co-CEO and Co-Founder, said, "We are thrilled to partner with ATHEX to explore the prospect of establishing a Voluntary Carbon Market for Greece.
  • -       The collaboration will foster the development of carbon markets in the region by granting access to a global carbon market.

ACX Partners With the Athens Stock Exchange in Greece to Develop Carbon Market in the region

Retrieved on: 
Tuesday, September 19, 2023
Carbon, Private sector, Partnership, ACX, United Nations, ABU, Carbon Market, United Nations Environment Programme Finance Initiative, Sustainable Stock Exchanges Initiative, Athens Exchange, SSE, Climate change, United, European, Entrepreneurship, Ecosystem, Renewable energy, EU

SINGAPORE, ATHENS, Greece and ABU DHABI, UAE, Sept. 19, 2023 /PRNewswire/ -- ACX (AirCarbon Exchange) and the Athens Stock Exchange (ATHEX) are delighted to establish a partnership to explore the development of a Voluntary Carbon Market in Greece, with the goal of creating a transparent and efficient market for Voluntary Carbon Credits.

Key Points: 
  • SINGAPORE, ATHENS, Greece and ABU DHABI, UAE, Sept. 19, 2023 /PRNewswire/ -- ACX (AirCarbon Exchange) and the Athens Stock Exchange (ATHEX) are delighted to establish a partnership to explore the development of a Voluntary Carbon Market in Greece, with the goal of creating a transparent and efficient market for Voluntary Carbon Credits.
  • This is the latest step in ACX's bold ambition to operate the world's largest environmental exchange network and the new Carbon Market in Greece will represent ACX's first base in continental Europe.
  • Thomas McMahon, ACX Co-CEO and Co-Founder, said, "We are thrilled to partner with ATHEX to explore the prospect of establishing a Voluntary Carbon Market for Greece.
  • -       The collaboration will foster the development of carbon markets in the region by granting access to a global carbon market.